Skip to main content

Premium on Gland Pharma shares declines significantly in grey market ahead of listing

In fact the premium has consistently been falling since the announcement of price band for its IPO in first week of November.

The share price premium of Gland Pharma in the grey market has significantly fallen ahead of the listing of shares later this week, despite the market being flooded with FII money and being traded at record high levels.

Shares are available at a premium of just Rs 6-10 in the grey market compared to its IPO price of Rs 1,500 per share, people familiar with the primary market development told Moneycontrol.



In fact, the premium has been falling consistently since the announcement of price band for its IPO in the first week of November. It was trading at a premium of Rs 200 per share just before the declaration of IPO price band, but then the premium fell to around Rs 60-70 and after closing of IPO, it further fell to Rs 35-40.

The high valuations and tepid response from investors (barring QIBs) could be some of key reasons for a decline in grey market premium.

"Uncertainty and lacked confidence from investors as a fact that 74 percent of Gland Pharma is owned by Chinese drug firm Fosun Pharma hurt local demand. Anti-Chinese sentiment due to the border dispute may have played a role in the reticence shown by domestic investors. As far as valuations are concerned even that was bit rich when compared to large pharma players in India and surprisingly we have seen huge rallies in pharma stocks in the past year which now trends low interest in new pharma entries," Prashanth Tapse, AVP Research at Mehta Equities told Moneycontrol.

"On overall basis institutional participation was also subdued compared to some other recent IPOs which is getting reflected in lower grey demand and supply before listing. Hence only high-risk long-term investors may hold rest allotted investors we advise to exit on decent listing," he said.

The pharma sector itself, especially after COVID-19 crisis, witnessed stellar rally given the huge healthcare demand. Nifty Pharma index climbed 83 percent from its March 23's low point.

The company launched its IPO during November 9-11, which was subscribed only 2.06 times. Only qualified institutional buyers helped the issue get subscribed as their reserved portion witnessed subscription of 6.4 times, while the response from retail investors (24 percent) and non-institutional investors (51 percent) was largely muted.

Gland Pharma, which is owned by China's Fosun Pharma, is expected to debut on bourses on November 20. Eligible investors are likely to get shares in their accounts by November 19 after the finalisation of basis of allotment around November 17.

The company raised Rs 6,480 crore via public issue, the second largest IPO after SBI Cards and Payment Services (Rs 10,355 crore) in 2020.

The public issue had comprised a fresh issue of Rs 1,250 crore and an offer for sale of over 3.48 crore shares by promoter and other selling shareholders.

Gland Pharma will utilise net proceeds from its fresh issue for funding incremental working capital requirements, funding capital expenditure requirements and general corporate purposes, while the promoter and selling shareholders received offer for sale money.

Source- Moneycontrol.com

Comments

Post a Comment

Popular posts from this blog

Tata Realty looks to list 20 million sq ft of commercial assets as REIT

  The existing land bank has potential of 20 million sq. ft commercial development in the next three to four years, says CEO Sanjay Dutt Tata Realty and Infrastructure (TRIL) is planning to list its Real Estate Investment Trust (REIT) with a portfolio of 20 million sq ft of commercial assets in the next few years. This will be done after the portfolio is expanded from present 6.2 million sq ft to 20 million sq ft via new developments and acquisitions. Sanjay Dutt, managing director and chief executive officer of TRIL told The Economic Times that the existing land bank has potential of 20 million sq ft commercial development in the next three to four years. The portfolio may also include office spaces and data centre assets. He added that his team has looked at least four proposals from developers looking to monetise their portfolios including single assets and carved-out portfolios across the country. “We are targeting a 45-50 million sq ft in commercial portf...
Post a Comment
Read more

Max India shares fall 5% on relisting day

  Max India resumed trading on BSE and NSE on August 28. The company, earlier known as Advaita Allied Health Services Limited, is a part of the $3-billion Max Group. Even as the broader market sentiment was bullish, shares of Max India fell 5 percent on BSE on the day of its relisting. The stock debuted at Rs 80 on BSE but fell 5 percent soon to touch its lower price band at Rs 76 on August 28. Max India resumed trading on BSE and NSE on August 28. The company, earlier known as Advaita Allied Health Services Limited, is a part of the $3-billion Max Group. The new Max India is the holding company of Max Group’s senior-care business Antar and the skilling company Max Skill First. The relisting of Max India follows Max Healthcare’s listing last week. In a media release, the company said listings are the outcome of a comprehensive scheme announced last year that involved a series of transactions, including the demerger of KKR-backed Radiant Lifecare’s assets into Max ...
Post a Comment
Read more

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...
Post a Comment
Read more